The hybrid conference will be held from Oct. 11–15 at the
Oral Presentation
Title: Early Experience with Omadacycline for the Treatment of Diabetic Foot Infections*
Presenter:
Session/time/location: Oral session 264 - Skin, Bone & Joint Infections;
Poster Presentations
Title: A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects*
Poster #: 277
Presenter:
Session/time/location: Basic Science and Translational Studies;
Title: Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in
Poster #: 1292
Presenter:
Session/time/location: Bone and Joint;
Title: High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from
Poster #: 2139
Presenter: Lalitagauri Deshpande, Ph.D.
Session/time/location: Antimicrobial Novel Agents;
Other Paratek Events at IDWeek 2023
Paratek invites attendees to visit the company’s onsite Booth #1024 from Oct. 11–15 and to participate in the following events:
- Product theater featuring guest speaker
George Sakoulas , M.D., onFri., Oct. 13 , 11:15–noon inLearning Lounge 2. - Medical Affairs learning lounge presentation, "CAP in the outpatient setting: Unmet needs and current treatment challenges," featuring guest speaker
Teena Chopra , M.D., M.P.H., onSat., Oct. 14 , 10:15–11:00 a.m. inLearning Lounge 2.
About
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed
In 2019, Paratek was awarded a contract from the
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
About NUZYRA®
NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and other drug-resistant strains.
MEDIA CONTACT:
Scient PR
Christine@ScientPR.com
215-595-5211
Source:
2023 GlobeNewswire, Inc., source